📊 LNTH Key Takeaways
Is Lantheus Holdings, Inc. (LNTH) a Good Investment?
Lantheus demonstrates exceptional financial health with 61.2% gross margins, 31.4% net margins, and strong free cash flow generation of $79.8M. The company maintains fortress-like liquidity (2.83x current ratio) and conservative leverage (0.47x debt/equity), providing financial flexibility and downside protection. However, near-zero revenue growth (+0.5% YoY) and declining diluted EPS (-21.8% YoY) indicate a mature business model with limited organic expansion, warranting a Buy rating for value/income investors rather than growth investors.
Fundamentals are strong: high margins (61% gross, 20% operating), robust free cash flow (22% FCF margin), and conservative leverage with ample liquidity and 64x interest coverage. While top-line growth is essentially flat (+0.5% YoY) and diluted EPS declined on share count effects, ROE remains strong at 21% and cash generation is durable. A reacceleration in revenue or sustained margin strength can translate into continued compounding of earnings and FCF from a solid base.
Lantheus Holdings, Inc. Key Strengths (LNTH)
- Exceptional profitability: 61.2% gross margin and 31.4% net margin demonstrate strong pricing power and operational efficiency in diagnostic products
- Strong free cash flow: $79.8M FCF with 21.1% FCF margin indicates high-quality earnings conversion and capital generation
- Conservative financial structure: 0.47x debt/equity ratio, 16.7x interest coverage, and $498.6M cash position provide significant financial cushion
- Excellent liquidity: 2.83x current ratio and 2.64x quick ratio indicate robust ability to meet short-term obligations
- High profitability with strong gross/operating margins and ROE/ROA
- Excellent cash conversion and low capex intensity supporting a 22.4% FCF margin
- Healthy balance sheet and liquidity with modest leverage and very high interest coverage
LNTH Stock Risks: Lantheus Holdings, Inc. Investment Risks
- Stagnant revenue growth: +0.5% YoY revenue increase suggests a mature market with limited organic growth catalysts or competitive pressures
- Declining shareholder returns: 21.8% YoY diluted EPS decline despite flat net income indicates share dilution offsetting operational performance
- Moderate capital efficiency: ROE of 9.8% and ROA of 5.0% suggest accumulated capital is not generating exceptional returns
- Sector headwinds: In vitro/in vivo diagnostics face ongoing pricing pressures, reimbursement challenges, and technological disruption
- Stagnant revenue growth suggesting maturing products or competitive pressure
- EPS dilution from higher share count despite flat net income
- Regulatory and reimbursement exposure typical for diagnostic substances businesses
Key Metrics to Watch
- Revenue growth acceleration from current 0.5% baseline to demonstrate market expansion
- Share count trend and EPS accretion/dilution to assess shareholder value creation
- Free cash flow sustainability and capital allocation decisions (buybacks vs. debt reduction vs. R&D investment)
- Gross margin trends as diagnostic pricing environment evolves
- YoY revenue growth trajectory
- Diluted shares outstanding trend
Lantheus Holdings, Inc. (LNTH) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 21.1% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 2.83x current ratio provides a solid financial cushion.
LNTH Profit Margin, ROE & Profitability Analysis
LNTH vs Healthcare Sector: How Lantheus Holdings, Inc. Compares
How Lantheus Holdings, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Lantheus Holdings, Inc. Stock Overvalued? LNTH Valuation Analysis 2026
Based on fundamental analysis, Lantheus Holdings, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Lantheus Holdings, Inc. Balance Sheet: LNTH Debt, Cash & Liquidity
LNTH Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Lantheus Holdings, Inc.'s revenue has grown significantly by 263% over the 5-year period, indicating strong business expansion. The most recent EPS of $4.65 reflects profitable operations.
LNTH Revenue Growth, EPS Growth & YoY Performance
LNTH Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $372.8M | $72.9M | $1.02 |
| Q3 2025 | $378.7M | $27.8M | $0.41 |
| Q2 2025 | $378.0M | $62.1M | $0.88 |
| Q1 2025 | $370.0M | $72.9M | $1.02 |
| Q3 2024 | $319.9M | -$2.8M | $1.79 |
| Q2 2024 | $321.7M | -$2.8M | $0.88 |
| Q1 2024 | $300.8M | -$2.8M | $-0.04 |
| Q3 2023 | $239.3M | -$2.8M | $0.86 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Lantheus Holdings, Inc. Dividends, Buybacks & Capital Allocation
LNTH SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Lantheus Holdings, Inc. (CIK: 0001521036)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LNTH
What is the AI rating for LNTH?
Lantheus Holdings, Inc. (LNTH) has a Combined AI Grade of A from Claude (A) and ChatGPT (A) with 72% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are LNTH's key strengths?
Claude: Exceptional profitability: 61.2% gross margin and 31.4% net margin demonstrate strong pricing power and operational efficiency in diagnostic products. Strong free cash flow: $79.8M FCF with 21.1% FCF margin indicates high-quality earnings conversion and capital generation. ChatGPT: High profitability with strong gross/operating margins and ROE/ROA. Excellent cash conversion and low capex intensity supporting a 22.4% FCF margin.
What are the risks of investing in LNTH?
Claude: Stagnant revenue growth: +0.5% YoY revenue increase suggests a mature market with limited organic growth catalysts or competitive pressures. Declining shareholder returns: 21.8% YoY diluted EPS decline despite flat net income indicates share dilution offsetting operational performance. ChatGPT: Stagnant revenue growth suggesting maturing products or competitive pressure. EPS dilution from higher share count despite flat net income.
What is LNTH's revenue and growth?
Lantheus Holdings, Inc. reported revenue of $377.3M.
Does LNTH pay dividends?
Lantheus Holdings, Inc. pays dividends, with $0.1M distributed to shareholders in the trailing twelve months.
Where can I find LNTH SEC filings?
Official SEC filings for Lantheus Holdings, Inc. (CIK: 0001521036) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LNTH's EPS?
Lantheus Holdings, Inc. has a diluted EPS of $1.80.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is LNTH's fundamental grade?
Based on our AI fundamental analysis in May 2026, Lantheus Holdings, Inc. has a A grade with 72% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is LNTH stock overvalued or undervalued?
Valuation metrics for LNTH: ROE of 9.8% (sector avg: 15%), net margin of 31.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is LNTH's AI grade for 2026?
Our dual AI analysis gives Lantheus Holdings, Inc. a combined A grade for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is LNTH's free cash flow?
Lantheus Holdings, Inc.'s operating cash flow is $125.1M, with capital expenditures of $45.3M. FCF margin is 21.1%.
How does LNTH compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 31.4% (avg: 12%), ROE 9.8% (avg: 15%), current ratio 2.83 (avg: 2).